Press release
Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast 2032: Epidemiology Analysis, Therapies and Treatment landscape by DelveInsight| Companies - Biomarin Pharmaceutical, Lysogene, Roche, Biogen, Sangamo and Pfizer
Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market
To know more about Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Report @ @ https://www.delveinsight.com/report-store/adeno-associated-virus-vectors-in-gene-therapy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some facts of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy report:
1. The AAV based gene therapies market size in the United States was valued to be USD 428 million in 2019.
2. In the year 2020, the total prevalent cases of selected indications for AAV Gene Therapies were 2,863,103 in the 7MM.
3. In EU-5 countries the highest number of prevalent cases were in Germany, i.e., 441,670 in the year 2020.
4. The total prevalent cases of Hemophilia A and Hemophilia B were reported to be 43,243 and 10,811 in 2020.
5. In the United Kingdom, the total treated cases of Parkinson's disease and Spinal Muscular Atrophy were 32,255 and 949, respectively, in the year 2020.
Get more comprehensive insights into how Adeno-Associated Virus (AAV) Vector-Based Gene Therapy epidemiological trends are impacting current and forecasted Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market @ https://www.delveinsight.com/sample-request/adeno-associated-virus-vectors-in-gene-therapy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Benefits of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Report:
• The report covers the descriptive overview of Adeno-Associated Virus Vectors in Gene Therapy, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Adeno-Associated Virus Vectors in Gene Therapy epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Adeno-Associated Virus Vectors in Gene Therapy are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Adeno-Associated Virus Vectors in Gene Therapy market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Adeno-Associated Virus Vectors in Gene Therapy market
To know more about the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market report offerings, click here @ Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Insight - @ https://www.delveinsight.com/sample-request/adeno-associated-virus-vectors-in-gene-therapy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
The key players in Adeno-Associated Virus Vectors in Gene Therapy market are:
• Valoctocogene Roxaparvovec (BMN 270): BioMarin Pharmaceutical: Phase III
• PF-06939926: Pfizer: Phase III
• Fidanacogene elaparvovec: Pfizer (initiated by Spark Therapeutics): Phase III
• AMT-061: uniQure/CSL Behring: Phase III
• Timrepigene emparvovec (BIIB111): NightstaRx Ltd, a Biogen Company: Phase III
• Giroctocogene fitelparvovec (SB-525): Pfizer (previously Sangamo Biosciences): Phase III
• BIIB112 (AAV8-RPGR): NightstaRx Ltd, a Biogen Company: Phase II/III
• NLX P101 (AAV-GAD): MeiraGTx: Phase II
• VY-AADC (NBIb-1817/ AAV2-hAADC): Neurocrine Biosciences/ Voyager Therapeutics: Phase II
• SPK-8011: Roche (previously Spark Therapeutics)/Pfizer: Phase I/II
• ST-920: Sangamo Therapeutics: Phase I/II
• FLT190: Freeline Therapeutics: Phase I/II
• SPK-3006 (AAV-sec-GAA): Spark Therapeutics: Phase I/II
• ACTUS-101: Asklepios Biopharmaceutical (Actus Therapeutics): Phase I/II
• AT845: Audentes Therapeutics: Phase I/II
• SRP-9001: Roche/Sarepta Therapeutics: Phase I/IIa
• HORA-PDE6B: Horama S.A.: Phase I/II
• AAV-RPGR (AAV2/5-RPGR): MeiraGTx UK II Ltd: Phase I/II
• RGX-121: RegenxBio: Phase I/II
• SB-913: Sangamo Therapeutics: Phase I/II
• AT-GTX-501 (scAAV9.CB.CLN6): Amicus Therapeutics: Phase I/IIa
• AT-GTX-502 (scAAV9.P546.CLN3): Amicus Therapeutics: Phase I/IIa
To know in detail about the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy treatment landscape, click here: Adeno-Associated Virus (AAV) Vector-Based Gene Therapy companies and drugs - @ https://www.delveinsight.com/sample-request/adeno-associated-virus-vectors-in-gene-therapy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Adeno-associated virus (AAV) belongs to the genus Dependoparvovirus within the family Parvoviridae. Its life cycle is dependent on the presence of a helper virus, such as AdV, hence its name and taxonomy classification. AAV is found in multiple vertebrate species, including human and non-human primates (NHPs). The current consensus is that AAV does not cause any human diseases. It is composed of an icosahedral protein capsid of ~26 nm in diameter and a single-stranded DNA genome of ~4.7 kb that can either be the plus (sense) or minus (anti-sense) strand.AAV vectors are the leading platform for gene delivery for the treatment of a variety of human diseases.
Recent advances in developing clinically desirable AAV capsids, optimizing genome designs, and harnessing revolutionary biotechnologies have contributed substantially to the growth of the gene therapy field.
Preclinical and clinical successes in AAV-mediated gene replacement, gene silencing, and gene editing have helped AAV gain popularity as the ideal therapeutic vector, with few AAV-based therapeutics gaining regulatory approval in Europe and the United States.
Do you want to know how much market share the emerging therapies are going to capture by 2032? Contact: Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Outlook - @ https://www.delveinsight.com/sample-request/adeno-associated-virus-vectors-in-gene-therapy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents:
1. Key Insights
2. Executive Summary of Adeno-Associated Virus Vectors in Gene Therapy
3. Competitive Intelligence Analysis for Adeno-Associated Virus Vectors in Gene Therapy
4. Adeno-Associated Virus Vectors in Gene Therapy: Market Overview at a Glance
5. Adeno-Associated Virus Vectors in Gene Therapy: Disease Background and Overview
6. Patient Journey
7. Adeno-Associated Virus Vectors in Gene Therapy Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Unmet Needs
10. Key Endpoints of Adeno-Associated Virus Vectors in Gene Therapy Treatment
11. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Marketed Products
12. Emerging Adeno-Associated Virus (AAV) Vector-Based Gene Therapies
13. Adeno-Associated Virus Vectors in Gene Therapy: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Outlook
16. Access and Reimbursement Overview of Adeno-Associated Virus Vectors in Gene Therapy
17. KOL Views
18. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Drivers
19. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
To know more about Emerging Adeno-Associated Virus (AAV) Vector-Based Gene Therapies, click here: Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Treatment Scenario- @ https://www.delveinsight.com/sample-request/adeno-associated-virus-vectors-in-gene-therapy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Trending Reports:
• Anaphylaxis Market: https://www.delveinsight.com/report-store/anaphylaxis-market
• Aortic Stenosis Market: https://www.delveinsight.com/report-store/aortic-stenosis-market
• Cluster Headaches Market: https://www.delveinsight.com/report-store/cluster-headache-market
• Familial Primary Pulmonary Hypertension Market: https://www.delveinsight.com/report-store/familial-primary-pulmonary-hypertension-market
• Hpv-induced Cancers Market: https://www.delveinsight.com/report-store/hpv-induced-cancers-market
• Meningioma Market: https://www.delveinsight.com/report-store/meningioma-market
• Optic Neuritis Market: https://www.delveinsight.com/report-store/optic-neuritis-market
• Partial Seizure Market: https://www.delveinsight.com/report-store/partial-seizure-market
• Progressive Multifocal Leukoencephalopathy Market: https://www.delveinsight.com/report-store/progressive-multifocal-leukoencephalopathy-market
• Rhino Conjunctivitis Market: https://www.delveinsight.com/report-store/rhino-conjunctivitis-market
• Thymic Carcinoma Market: https://www.delveinsight.com/report-store/thymic-carcinoma-market
• Pulse Oximeters Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Chronic Lymphocytic Leukemia Market: https://www.delveinsight.com/report-store/relapsed-chronic-lymphocytic-leukemia-cll-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Aesthetic Implants Market: https://www.delveinsight.com/report-store/aesthetic-implants-market
• Multiple Myeloma Market: https://www.delveinsight.com/report-store/multiple-myeloma-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Lewy Body Dementia Market: https://www.delveinsight.com/report-store/lewy-body-dementia-market
• Alopecia Market: https://www.delveinsight.com/report-store/alopecia-market
• Neurostimulation Devices Market: https://www.delveinsight.com/report-store/neurostimulation-devices-market
• Pruritus Market: https://www.delveinsight.com/report-store/pruritus-market
• Eczema Market: https://www.delveinsight.com/report-store/eczema-market
• Concussions Market Size: https://www.delveinsight.com/report-store/concussions-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Human Papilomavirus Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market
• Blood Gas And Electrolyte Analyzers Market: https://www.delveinsight.com/report-store/blood-gas-and-electrolyte-analyzers-market
• Actinic Keratosis Market: https://www.delveinsight.com/report-store/actinic-keratosis-market
• Alzheimer Disease Market: https://www.delveinsight.com/report-store/alzheimers-disease-ad-market
• Chemotherapy Induced Thrombocytopenia Market: https://www.delveinsight.com/report-store/chemotherapy-induced-thrombocytopenia-market-size
• Foot And Ankle Devices Market: https://www.delveinsight.com/report-store/foot-and-ankle-devices-market
• Parkinson's Disease Market: https://www.delveinsight.com/report-store/parkinsons-disease-market-size-analysis-treatment
• Ventilator Market: https://www.delveinsight.com/report-store/ventilators-market
Contact us
Ankit Nigam
info@delveinsight.com
+91-9650213330
https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast 2032: Epidemiology Analysis, Therapies and Treatment landscape by DelveInsight| Companies - Biomarin Pharmaceutical, Lysogene, Roche, Biogen, Sangamo and Pfizer here
News-ID: 3289158 • Views: …
More Releases from DelveInsight Business Research
Global Tumor Ablation Market to reach USD 4,595.68 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The global Tumor Ablations (EHR) market is experiencing significant growth, driven by the increasing prevalence of chronic diseases that require continuous monitoring, data management, and coordinated long-term care. This demand has fueled the need for integrated healthcare systems capable of connecting patient information across multiple departments and care settings. To support this trend, governments worldwide are introducing initiatives, funding, mandates, and regulatory frameworks to promote EHR…
Global Spinal Implants Market to reach USD 21,899.24 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing prevalence of spinal disorders, especially among the aging population, has substantially driven the demand for corrective surgical procedures. At the same time, the rise in sports-related and trauma-induced spinal injuries is boosting the need for advanced implantable solutions. Additionally, there is a growing preference for non-fusion and motion-preserving devices that maintain spinal mobility and improve patient outcomes, particularly among younger and more active individuals.…
Global Vascular Stents Market to reach USD 18,277.68 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing global incidence of cancer is boosting the demand for effective treatment options such as tumor ablation. Minimally invasive procedures are becoming more popular due to their shorter recovery periods, reduced risks, and cost-effectiveness compared to conventional surgery. At the same time, technological advancements in tumor ablation devices-such as improvements in radiofrequency, microwave, and cryoablation technologies-have enhanced precision, safety, and effectiveness, making these procedures increasingly…
Global Vascular Grafts Market to reach USD 3,153.39 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The increasing prevalence of cardiovascular disorders, along with risk factors like hypertension, diabetes, and obesity, is fueling the demand for surgical interventions, thereby supporting the growth of the vascular graft market. Moreover, greater awareness and the expansion of cardiovascular screening programs are enabling earlier diagnosis and timely treatment, further driving the need for vascular grafts.
DelveInsight's "Vascular Grafts Market Insights, Competitive Landscape and Market Forecast-2032" report provides…
More Releases for AAV
AAV Vector Market to Reach USD 4 Billion by 2034, Growing at 12% CAGR
Introduction
The rise of gene therapy has transformed the treatment landscape for genetic disorders, rare diseases, and oncology. At the center of this revolution are adeno-associated virus (AAV) vectors, which provide safe, efficient, and long-term gene delivery. With FDA and EMA approvals for multiple AAV-based therapies, coupled with expanding clinical pipelines, the AAV vector market is emerging as one of the fastest-growing sectors in biotechnology.
In 2024, the AAV vector market was…
AAV Vector Transfection Kits Market Key Players, Share and Forecast Outlook
"The global market for AAV (Adeno-Associated Virus) vector transfection kits is poised for significant growth, currently valued at approximately $1.2 billion in 2024. This market is projected to reach around $3 billion by 2034, reflecting a robust compound annual growth rate (CAGR) of 9.5% during the forecast period of 2025-2034. "
Exactitude Consultancy., Ltd. released a research report titled "AAV Vector Transfection Kits Market". This report covers the global AAV Vector…
ProBio offers AAV One-stop Solution for AAV vector
AAV One-stop Solution
Process development for triple transfection
Support regulatory filing
AAV vector is widely used delivery vehicle due to its high safety and effectiveness in delivering Gene of Interest (GOI). ProBio is broadening its business in AAV services [https://www.probiocdmo.com/gct-one-stop-aav.html]to cater to the market demand.
Image: https://www.probiocdmo.com/img/probio/gct-one-stop-aav-banner.jpg
One-stop Solution for AAV
ProBio offers services from cell banking, process development, AAV packaging [https://www.probiocdmo.com/gct-one-stop-aav.html], analytical development, to GMP manufacturing and stability test for AAV vector. ProBio is also…
AAV Contract Development And Manufacturing Organizations Market 2024 Insights an …
In recent years, the global AAV Contract Development And Manufacturing Organizations Market has witnessed a dynamic shift, influenced by changing consumer preferences, technological advancements, and a growing emphasis on sustainability. The Research report on AAV Contract Development And Manufacturing Organizations Market presents a complete judgment of the market through strategic insights on future trends, growth factors, supplier landscape, demand landscape, Y-o-Y growth rate, CAGR, pricing analysis. It also provides and…
Adeno-Associated Virus (AAV) Vectors in Gene Therapy Pipeline Outlook Report 202 …
DelveInsight has released its latest report titled "AAV Vectors in Gene Therapy Pipeline Insight 2024" offering extensive insights into over 70 companies and more than 235 pipeline drugs within the AAV vectors gene therapy landscape. This comprehensive report includes detailed profiles of pipeline drugs across clinical and nonclinical stages, alongside thorough assessments based on product type, development stage, route of administration, and molecule type. Additionally, it features an analysis of…
Adeno-Associated Virus (AAV) CDMO Services Market Opportunities and Forecast 202 …
Data Library Research newly added a research report on the Adeno-Associated Virus (AAV) CDMO Services Market, which represents a study for the period from 2022 to 2029. The research study provides a near look at the market scenario and dynamics impacting its growth. This report highlights the crucial developments along with other events happening in the market which are marking on the growth and opening doors for future growth in…
